



# A new Ebola vaccine: the journey so far

Accelerating 10 years to 10 months

**Next steps...**

**Phase II**  
3,000 healthy adults and children in clinical trials  
▪ Mali, Nigeria, Ghana, Senegal, Cameroon

**Phase III**  
Trials due to start in  
▪ Guinea

Vaccines normally take 10-15 years to develop

GSK already collaborating with NIH to develop an Ebola vaccine

**First case of current strain of Ebola in West Africa**

Outbreak recognised as a major incident in Guinea (March 2014), Sierra Leone (May 2014) and Liberia (July 2014)

GSK shipped first batch of vaccine to Liberia

**Jan 2015**

Initial trials suggest candidate vaccine has acceptable benefit risk profile

Doses have been manufactured and are ready to be shipped

**Dec 2013**

GSK supports humanitarian aid partners, helping with critical supplies, equipment and training of additional health workers



Financial support ensures vaccine development stays on track

**Dec 2014**

£25m  
Partners commit a total of nearly £25m

**Mar 2014**

Grant from UK partners enables manufacture of new vaccine lots



- £11.1m European Commission (EC)
- £1.8m Bill & Melinda Gates Foundation
- £1.1m Swiss Government
- £2.8m UK partners
- £8m BARDA

Three countries primarily affected:  
▪ Guinea  
▪ Sierra Leone  
▪ Liberia

On 8 August, WHO declared the epidemic to be a "public health emergency of international concern."


- UK partners
- Wellcome Trust
  - Medical Research Council (MRC)
  - UK Department for International Development (DFID)

**Nov 2014**

**Phase I: 200 volunteers**  
▪ Mali  
▪ Switzerland  
▪ UK  
▪ USA

**Aug 2014**

GSK, together with private and public partners, form international consortium to accelerate the development of candidate vaccine



10,000  
GSK begin manufacturing another 10,000 doses

**Sept 2014**

Multiple trials run in parallel with the development of the manufacturing process. The aim is to have stocks ready if the trials are successful

Quality, safety and efficacy standards are fully observed

GSK begin manufacturing an additional 20,000 doses at the same time as initial clinical trials

